Latest news with #SangamoTherapeutics
Yahoo
13-05-2025
- Business
- Yahoo
Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ...
Release Date: May 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Sangamo Therapeutics Inc (NASDAQ:SGMO) signed a significant license agreement with Eli Lilly, potentially worth up to $1.4 billion in milestone payments. The company is advancing its neurology pipeline, with preparations for a Phase 1/2 study of ST 503 for chronic neuropathic pain. Sangamo has achieved important clinical and regulatory milestones for its Fabry disease program, with a pivotal data readout expected soon. The company has reduced non-GAAP operating expenses by 50% year-on-year, demonstrating financial discipline. Sangamo is actively engaging in promising business development discussions, indicating ongoing interest in its technology platforms. Sangamo Therapeutics Inc (NASDAQ:SGMO) requires additional capital to fund its operations and achieve proof of concept in its programs. The company is reliant on securing a commercial partnership for its Fabry disease program to ensure long-term funding. There is uncertainty regarding the statistical analysis plan for the EGFR data, which is crucial for regulatory submissions. The company faces challenges in the broader macroeconomic landscape, including potential impacts from drug pricing discussions. Sangamo's immediate cash runway is limited, necessitating a recent equity offering to extend its financial runway. Warning! GuruFocus has detected 7 Warning Signs with SGMO. Q: Could you provide more color on what exactly you plan to show in the top line EGFR data? Will you show just the EGFR slope or other quality of life endpoints? Also, will there be an NHS analysis to contextualize the improvements in EGFR? A: We will share the updated mean EGFR slope in the top line data and comment on additional information at a later date. We have agreed with the FDA on our statistical analysis plan, but we are not commenting on specifics at this time. Q: How many potential partners are you currently in conversations with regarding a potential Fabry partnership, and what can you tell us about those discussions? A: We are in discussions with multiple potential partners. The recent Type B meeting with the FDA was helpful, providing a clear path for CMC, which is crucial for any gene therapy BLA and approval. Q: Given the current administration's concern around drug pricing, how do you think that will impact gene therapy uptake and pricing in the US and abroad? A: There is a long way to go in discussions around drug pricing. The pharmaceutical industry is important in America, and BIO will be having detailed conversations with the administration to find a productive way forward. Q: Do you still plan to file based on 52-week EGFR data for Fabry, and is static versus baseline required for EGFR? A: Yes, we are pursuing the agreement with the FDA to use 52-week EGFR data for the entire patient population in the phase one study. We have collected all the data and expect to share the topline data at the end of the quarter, which will be the basis for our BLA. Q: Are the patients who were on ERT still off ERT, or were there any relapses? A: Yes, all 18 patients who started on ERT out of our 32 patients are still off ERT. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
13-05-2025
- Business
- Business Insider
Sangamo reports Q1 EPS (14c) vs (27c) last year
Reports Q1 revenue $6.44M, consensus $7.42M. 'This quarter we continued to advance our promising neurology genomic medicine pipeline and are pleased to have signed our third STAC-BBB license agreement, reinforcing that Sangamo (SGMO) is a collaborator of choice for neurotropic capsids,' said Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics. 'We achieved significant clinical and regulatory derisking milestones in our Fabry disease program and raised additional capital through business development and other means, to provide additional runway to secure a potential Fabry partner. With our neuropathic pain program ready to enter the clinic, we look forward to dosing the first patients with our epigenetic regulation technology, which we hope will usher in a new era in chronic pain treatment.' Protect Your Portfolio Against Market Uncertainty
Business Wire
12-05-2025
- Business
- Business Wire
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 12,235,000 shares of its common stock and pre-funded warrants to purchase 34,398,393 shares of its common stock, together with accompanying warrants to purchase 46,633,393 shares of its common stock. The combined offering price of each share of common stock and accompanying warrant is $0.50. The combined offering price of each pre-funded warrant and accompanying warrant is $0.49. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase one share of common stock issued for each share of common stock or pre-funded warrant sold. The accompanying warrant has an exercise price of $0.75 per share, will become exercisable six months from the date of issuance and will expire six years from the date of issuance. All of the securities in the offering are to be sold by Sangamo. The offering is expected to close on or about May 14, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds to Sangamo from this underwritten offering, before deducting the underwriting discount and other estimated offering expenses, are expected to be approximately $23.0 million. Sangamo intends to use the net proceeds from the offering for working capital and general corporate purposes. Cantor is acting as sole book-running manager for the offering. A shelf registration statement on Form S-3 relating to the offering of the securities described above was previously filed with the Securities and Exchange Commission (SEC) and subsequently declared effective by the SEC. The offering is being made solely by means of a prospectus. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website located at A copy of the final prospectus supplement and accompanying prospectus relating to the offering, when available, may be obtained by investors for free from: Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59 th Street, 6th floor, New York, New York 10022; by email at prospectus@ This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Sangamo Therapeutics Sangamo Therapeutics is a genomic medicine company dedicated to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases who do not have adequate or any treatment options. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system. Sangamo's pipeline also includes multiple partnered programs and programs with opportunities for partnership and investment. Forward Looking Statements This press release contains forward-looking statements regarding Sangamo's current expectations. These forward-looking statements include, without limitation, references to Sangamo's expectations regarding the completion of the offering and its anticipated use of net proceeds from the offering. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to completion of the offering on the anticipated terms or at all; the effects of macroeconomic factors or financial challenges, including as a result of the ongoing overseas conflict, tariffs and trade measures, inflation and rising interest rates, on the global business environment, healthcare systems and business and operations of Sangamo and its collaborators, including the initiation and operation of clinical trials; and the satisfaction of customary closing conditions related to the offering. These and other risks and uncertainties are described more fully in the section captioned "Risk Factors" in Sangamo's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 17, 2025 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed with the SEC on May 12, 2025, as well as the final prospectus supplement related to the offering to be filed with the SEC and other filings. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.
Yahoo
12-05-2025
- Business
- Yahoo
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering
RICHMOND, Calif., May 12, 2025--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 12,235,000 shares of its common stock and pre-funded warrants to purchase 34,398,393 shares of its common stock, together with accompanying warrants to purchase 46,633,393 shares of its common stock. The combined offering price of each share of common stock and accompanying warrant is $0.50. The combined offering price of each pre-funded warrant and accompanying warrant is $0.49. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase one share of common stock issued for each share of common stock or pre-funded warrant sold. The accompanying warrant has an exercise price of $0.75 per share, will become exercisable six months from the date of issuance and will expire six years from the date of issuance. All of the securities in the offering are to be sold by Sangamo. The offering is expected to close on or about May 14, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds to Sangamo from this underwritten offering, before deducting the underwriting discount and other estimated offering expenses, are expected to be approximately $23.0 million. Sangamo intends to use the net proceeds from the offering for working capital and general corporate purposes. Cantor is acting as sole book-running manager for the offering. A shelf registration statement on Form S-3 relating to the offering of the securities described above was previously filed with the Securities and Exchange Commission (SEC) and subsequently declared effective by the SEC. The offering is being made solely by means of a prospectus. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website located at A copy of the final prospectus supplement and accompanying prospectus relating to the offering, when available, may be obtained by investors for free from: Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th floor, New York, New York 10022; by email at prospectus@ This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Sangamo Therapeutics Sangamo Therapeutics is a genomic medicine company dedicated to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases who do not have adequate or any treatment options. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system. Sangamo's pipeline also includes multiple partnered programs and programs with opportunities for partnership and investment. Forward Looking Statements This press release contains forward-looking statements regarding Sangamo's current expectations. These forward-looking statements include, without limitation, references to Sangamo's expectations regarding the completion of the offering and its anticipated use of net proceeds from the offering. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to completion of the offering on the anticipated terms or at all; the effects of macroeconomic factors or financial challenges, including as a result of the ongoing overseas conflict, tariffs and trade measures, inflation and rising interest rates, on the global business environment, healthcare systems and business and operations of Sangamo and its collaborators, including the initiation and operation of clinical trials; and the satisfaction of customary closing conditions related to the offering. These and other risks and uncertainties are described more fully in the section captioned "Risk Factors" in Sangamo's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 17, 2025 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed with the SEC on May 12, 2025, as well as the final prospectus supplement related to the offering to be filed with the SEC and other filings. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law. View source version on Contacts Sangamo Contact Investor Relations Louise Wilkieir@ Media Inquiries Melinda Hutcheonmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Washington Post
12-05-2025
- Business
- Washington Post
Sangamo: Q1 Earnings Snapshot
RICHMOND, Calif. — RICHMOND, Calif. — Sangamo Therapeutics Inc. (SGMO) on Monday reported a loss of $30.6 million in its first quarter. The Richmond, California-based company said it had a loss of 14 cents per share. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 11 cents per share.
